Alan Lombard • UC Davis Profiles (original) (raw)

  1. Targeting NDUFS4 Disrupts Oxidative Phosphorylation and Induces Ferroptosis in Olaparib-Resistant Prostate Cancer. Mol Cancer Ther. 2026 Apr 09. Schaaf ZA, Ning S, Leslie AR, Sharifi M, Gao RY, Maine JP, Leslie KD, Shen Y, Lombard AP, Lou W, Li PK, Liu C, Dall'Era M, Gao AC. PMID: 41954274.
    View in: PubMed Mentions:
  2. IGFBP3-SphK1/S1P Signaling Axis Drives Enzalutamide Resistance in Advanced Prostate Cancer. Mol Cancer Ther. 2025 Dec 05. Leslie AR, Ning S, Sharifi M, Schaaf ZA, Maine JP, Lou W, Leslie KD, Liu C, Xu H, Lombard AP, Chen HW, Parikh M, Dall'Era M, Gao AC. PMID: 41347288; PMCID: PMC12795166.
    View in: PubMed Mentions: Fields:
  3. LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy. Cancer Res. 2024 Nov 04; 84(21):3617-3628. Ning S, Armstrong CM, Xing E, Leslie AR, Gao RY, Sharifi M, Schaaf ZA, Lou W, Han X, Xu DH, Yang R, Cheng J, Mohammed S, Mitsiades N, Liu C, Lombard AP, Wu CY, Cheng X, Li PK, Gao AC. PMID: 39088701; PMCID: PMC11534543.
    View in: PubMed Mentions: 3 Fields:
    Translation:HumansAnimalsCells
  4. PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells. Cancer Res Commun. 2024 11 01; 4(11):2976-2985. Schaaf ZA, Ning S, Leslie AR, Sharifi M, Gao RY, Maine JP, Lou W, Lombard AP, Liu C, Yu AM, Mitsiades N, Gao AC. PMID: 39440945; PMCID: PMC11577557.
    View in: PubMed Mentions: 1 Fields:
    Translation:HumansCells
  5. IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer. iScience. 2024 Feb 16; 27(2):108984. Leslie AR, Ning S, Armstrong CM, D'Abronzo LS, Sharifi M, Schaaf ZA, Lou W, Liu C, Evans CP, Lombard AP, Gao AC. PMID: 38327800; PMCID: PMC10847745.
    View in: PubMed Mentions: 6
  6. Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer. Cancers (Basel). 2023 Nov 03; 15(21). Schaaf ZA, Ning S, Leslie AR, Sharifi M, Han X, Armstrong C, Lou W, Lombard AP, Liu C, Gao AC. PMID: 37958444; PMCID: PMC10650051.
    View in: PubMed Mentions: 5
  7. Wntless expression promotes lineage plasticity and is associated with neuroendocrine prostate cancer. Am J Clin Exp Urol. 2022; 10(5):299-310. D'Abronzo LS, Lombard AP, Ning S, Armstong CM, Leslie AR, Sharifi M, Schaaf ZA, Lou W, Gao AC. PMID: 36313205; PMCID: PMC9605943.
    View in: PubMed Mentions: 3
  8. Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment. Mol Cancer Ther. 2022 10 07; 21(10):1594-1607. Ning S, Liu C, Lou W, Yang JC, Lombard AP, D'Abronzo LS, Batra N, Yu AM, Leslie AR, Sharifi M, Evans CP, Gao AC. PMID: 35930737; PMCID: PMC9547958.
    View in: PubMed Mentions: 14 Fields:
    Translation:HumansCells
  9. Activation of neural lineage networks and ARHGEF2 in enzalutamide-resistant and neuroendocrine prostate cancer and association with patient outcomes. Commun Med (Lond). 2022; 2:118. Ning S, Zhao J, Lombard AP, D'Abronzo LS, Leslie AR, Sharifi M, Lou W, Liu C, Yang JC, Evans CP, Corey E, Chen HW, Yu A, Ghosh PM, Gao AC. PMID: 36159187; PMCID: PMC9492734.
    View in: PubMed Mentions: 7
  10. Olaparib-Induced Senescence Is Bypassed through G2-M Checkpoint Override in Olaparib-Resistant Prostate Cancer. Mol Cancer Ther. 2022 04 01; 21(4):677-685. Lombard AP, Armstrong CM, D'Abronzo LS, Ning S, Leslie AR, Sharifi M, Lou W, Evans CP, Dall'Era M, Chen HW, Chen X, Gao AC. PMID: 35086956; PMCID: PMC8983570.
    View in: PubMed Mentions: 12 Fields:
    Translation:HumansCells
  11. Activation of the ABCB1 Amplicon in Docetaxel- and Cabazitaxel-Resistant Prostate Cancer Cells. Mol Cancer Ther. 2021 10; 20(10):2061-2070. Lombard AP, Lou W, Armstrong CM, D'Abronzo LS, Ning S, Evans CP, Gao AC. PMID: 34326198; PMCID: PMC8492550.
    View in: PubMed Mentions: 13 Fields:
    Translation:HumansCells
  12. ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling. Oncogene. 2021 Sep; 40(35):5379-5392. Liu C, Armstrong CM, Ning S, Yang JC, Lou W, Lombard AP, Zhao J, Wu CY, Yu A, Evans CP, Tepper CG, Li PK, Gao AC. PMID: 34272475; PMCID: PMC8413131.
    View in: PubMed Mentions: 18 Fields:
    Translation:HumansAnimalsCells
  13. Depletion of androgen receptor low molecular weight isoform reduces bladder tumor cell viability and induces apoptosis. Cancer Lett. 2021 04 28; 504:49-57. Katleba K, Lombard AP, Tsamouri MM, Baek HB, Nishida KS, Libertini SJ, Platero AJ, Ma AH, Pan CX, Ghosh PM, Mudryj M. PMID: 33549708; PMCID: PMC7943249.
    View in: PubMed Mentions: 7 Fields:
    Translation:Humans
  14. Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate Cancer. Clin Cancer Res. 2020 11 15; 26(22):6064-6074. Armstrong CM, Liu C, Liu L, Yang JC, Lou W, Zhao R, Ning S, Lombard AP, Zhao J, D'Abronzo LS, Evans CP, Li PK, Gao AC. PMID: 32928794; PMCID: PMC7669645.
    View in: PubMed Mentions: 10 Fields:
    Translation:HumansCells
  15. Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer. Mol Cancer Ther. 2020 08; 19(8):1708-1718. Zhao J, Ning S, Lou W, Yang JC, Armstrong CM, Lombard AP, D'Abronzo LS, Evans CP, Gao AC, Liu C. PMID: 32430485; PMCID: PMC8855880.
    View in: PubMed Mentions: 40 Fields:
    Translation:HumansCells
  16. The p14ARF tumor suppressor restrains androgen receptor activity and prevents apoptosis in prostate cancer cells. Cancer Lett. 2020 07 28; 483:12-21. Siddiqui S, Libertini SJ, Lucas CA, Lombard AP, Baek HB, Nakagawa RM, Nishida KS, Steele TM, Melgoza FU, Borowsky AD, Durbin-Johnson BP, Qi L, Ghosh PM, Mudryj M. PMID: 32330514; PMCID: PMC8034238.
    View in: PubMed Mentions: 3 Fields:
    Translation:HumansAnimalsCells
  17. Resistance Mechanisms to Taxanes and PARP Inhibitors in Advanced Prostate Cancer. Curr Opin Endocr Metab Res. 2020 Feb; 10:16-22. Lombard AP, Gao AC. PMID: 32258820; PMCID: PMC7111181.
    View in: PubMed Mentions: 4
  18. Wntless promotes cellular viability and resistance to enzalutamide in castration-resistant prostate cancer cells. Am J Clin Exp Urol. 2019; 7(4):203-214. Lombard AP, Liu C, Armstrong CM, D'Abronzo LS, Lou W, Evans CP, Gao AC. PMID: 31511827; PMCID: PMC6734040.
    View in: PubMed Mentions: 11
  19. AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer. Mol Cancer Ther. 2019 10; 18(10):1875-1886. Liu C, Yang JC, Armstrong CM, Lou W, Liu L, Qiu X, Zou B, Lombard AP, D'Abronzo LS, Evans CP, Gao AC. PMID: 31308078; PMCID: PMC6995728.
    View in: PubMed Mentions: 41 Fields:
    Translation:HumansAnimalsCells
  20. Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer. Transl Oncol. 2019 Jul; 12(7):871-878. Lombard AP, Liu C, Armstrong CM, D'Abronzo LS, Lou W, Chen H, Dall'Era M, Ghosh PM, Evans CP, Gao AC. PMID: 31075528; PMCID: PMC6510951.
    View in: PubMed Mentions: 17
  21. Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer. Nat Commun. 2018 11 16; 9(1):4700. Liu C, Lou W, Yang JC, Liu L, Armstrong CM, Lombard AP, Zhao R, Noel ODV, Tepper CG, Chen HW, Dall'Era M, Evans CP, Gao AC. PMID: 30446660; PMCID: PMC6240084.
    View in: PubMed Mentions: 68 Fields:
    Translation:HumansAnimalsCells
  22. XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies. Oncotarget. 2018 Oct 02; 9(77):34567-34581. Baek HB, Lombard AP, Libertini SJ, Fernandez-Rubio A, Vinall R, Gandour-Edwards R, Nakagawa R, Vidallo K, Nishida K, Siddiqui S, Wettersten H, Landesman Y, Weiss RH, Ghosh PM, Mudryj M. PMID: 30349650; PMCID: PMC6195388.
    View in: PubMed Mentions: 16 Fields:
  23. Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer. Mol Cancer Ther. 2018 10; 17(10):2197-2205. Lombard AP, Liu L, Cucchiara V, Liu C, Armstrong CM, Zhao R, Yang JC, Lou W, Evans CP, Gao AC. PMID: 29891490; PMCID: PMC6168406.
    View in: PubMed Mentions: 21 Fields:
    Translation:HumansCells
  24. ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer. Mol Cancer Ther. 2017 10; 16(10):2257-2266. Lombard AP, Liu C, Armstrong CM, Cucchiara V, Gu X, Lou W, Evans CP, Gao AC. PMID: 28698198; PMCID: PMC5628132.
    View in: PubMed Mentions: 40 Fields:
    Translation:HumansCells
  25. MicroRNA-181a promotes docetaxel resistance in prostate cancer cells. Prostate. 2017 Jun; 77(9):1020-1028. Armstrong CM, Liu C, Lou W, Lombard AP, Evans CP, Gao AC. PMID: 28485104; PMCID: PMC5448975.
    View in: PubMed Mentions: 19 Fields:
    Translation:HumansCells
  26. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer. Mol Cancer Ther. 2017 08; 16(8):1521-1530. Liu C, Armstrong CM, Lou W, Lombard AP, Cucchiara V, Gu X, Yang JC, Nadiminty N, Pan CX, Evans CP, Gao AC. PMID: 28500234; PMCID: PMC5544572.
    View in: PubMed Mentions: 29 Fields:
    Translation:HumansAnimalsCells
  27. Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer. Mol Cancer Ther. 2017 01; 16(1):35-44. Liu C, Armstrong CM, Lou W, Lombard A, Evans CP, Gao AC. PMID: 27794047; PMCID: PMC5222693.
    View in: PubMed Mentions: 64 Fields:
    Translation:HumansAnimalsCells
  28. The emerging role of the androgen receptor in bladder cancer. Endocr Relat Cancer. 2015 Oct; 22(5):R265-77. Lombard AP, Mudryj M. PMID: 26229034.
    View in: PubMed Mentions: 41 Fields:
    Translation:HumansCells
  29. Dicer ablation promotes a mesenchymal and invasive phenotype in bladder cancer cells. Oncol Rep. 2015 Sep; 34(3):1526-32. Lombard AP, Lim RM, Nakagawa RM, Vidallo KD, Libertini SJ, Platero AJ, Mudryj M. PMID: 26166215.
    View in: PubMed Mentions: 7 Fields:
    Translation:HumansCells
  30. miR-148a dependent apoptosis of bladder cancer cells is mediated in part by the epigenetic modifier DNMT1. Mol Carcinog. 2016 May; 55(5):757-67. Lombard AP, Mooso BA, Libertini SJ, Lim RM, Nakagawa RM, Vidallo KD, Costanzo NC, Ghosh PM, Mudryj M. PMID: 25865490; PMCID: PMC4600638.
    View in: PubMed Mentions: 24 Fields:
    Translation:HumansCells

This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.

This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.

Start with: newest oldestInclude: line numbers double spacing all authors publication IDs